What are the recommended next steps for a patient with a 0.68 cm left thyroid isoechoic nodule classified as American College of Radiology Thyroid Imaging Reporting and Data System (ACR‑TIRADS) TR 3 and a 0.58 cm right thyroid anechoic cyst classified as ACR‑TIRADS TR 1?

Management of TR3 Left Thyroid Nodule (0.68 cm) and TR1 Right Thyroid Cyst (0.58 cm)

For your 0.68 cm TR3 left thyroid nodule, no fine-needle aspiration is needed—proceed with ultrasound surveillance at 1,3, and 5 years; the right thyroid cyst requires no further action. 1

Understanding Your ACR TI-RADS Classifications

Right Thyroid Lobe (TR1 – Benign Cyst)

• The 0.58 cm anechoic lesion with regular borders and no vascularity is a simple benign cyst that requires no FNA and no follow-up imaging. 1
• Pure cystic nodules without solid components carry essentially zero malignancy risk and can be safely observed without intervention. 2

Left Thyroid Lobe (TR3 – Mildly Suspicious Nodule)

• Your 0.68 cm isoechoic nodule with regular margins and peripheral vascularity falls below the 2.5 cm threshold for FNA in TR3 nodules. 1, 2
• TR3 nodules between 1.5–2.4 cm warrant surveillance ultrasound at 1,3, and 5 years; nodules smaller than 1.5 cm (like yours at 0.68 cm) require even less aggressive monitoring. 1

Recommended Management Algorithm

Immediate Next Steps

• Measure serum TSH to exclude autonomous thyroid hormone production. 3
• No fine-needle aspiration is indicated at this time because your nodule is both too small (<1.5 cm) and lacks high-risk features that would lower the FNA threshold. 2

Surveillance Protocol for the TR3 Nodule

• Schedule follow-up ultrasound at 12 months, then at 3 years, then at 5 years to monitor for interval growth or development of suspicious features. 1, 2
• At each surveillance scan, document any change in size (≥3 mm growth in any dimension is significant) and assess for new high-risk features including marked hypoechogenicity, microcalcifications, irregular margins, or loss of peripheral halo. 2

When to Proceed to FNA During Surveillance

• Perform ultrasound-guided FNA if the nodule grows to ≥2.5 cm during follow-up, even if it maintains benign-appearing features. 1, 2
• Perform FNA earlier (at ≥1.5 cm) if the nodule develops suspicious features such as microcalcifications, irregular borders, marked hypoechogenicity, or central hypervascularity. 2
• Perform FNA regardless of size if you develop high-risk clinical factors including compressive symptoms (dysphagia, dyspnea, voice changes), suspicious cervical lymphadenopathy on ultrasound, or rapid growth (≥3 mm increase in any dimension). 2

Critical Clinical Context That Would Change Management

High-Risk Factors That Lower the FNA Threshold

Although your current nodule does not meet criteria for immediate FNA, any of the following would warrant earlier biopsy even for nodules <1.5 cm: 2

• History of head and neck irradiation (increases malignancy risk approximately 7-fold)
• Family history of thyroid cancer, particularly medullary carcinoma or familial syndromes
• Age <15 years or male gender (higher baseline malignancy probability)
• Firm, fixed nodule on palpation (suggests extrathyroidal extension)
• Vocal cord paralysis or compressive symptoms
• Suspicious cervical lymphadenopathy (loss of fatty hilum, microcalcifications, cystic change, abnormal vascularity)
• Focal FDG uptake on PET scan if performed for other indications

Heterogeneous Echotexture Finding

• The heterogeneous echotexture of your thyroid gland likely represents chronic thyroiditis (Hashimoto's) or multinodular changes. 4
• This background pattern does not independently increase malignancy risk but makes it more important to characterize discrete nodules carefully. 2
• Measure serum TSH and consider thyroid peroxidase antibodies (TPO-Ab) if TSH is elevated to confirm underlying autoimmune thyroiditis. 3

What NOT to Do

Avoid These Common Pitfalls

• Do not order a thyroid radionuclide scan in the setting of normal or elevated TSH—it provides no useful information for malignancy risk assessment in euthyroid patients. 1
• Do not order CT or MRI for routine thyroid nodule characterization—ultrasound provides superior resolution and avoids unnecessary radiation or cost. 1
• Do not perform FNA on the 0.68 cm TR3 nodule now simply because it has peripheral vascularity—this would lead to overdiagnosis of clinically insignificant papillary microcarcinomas without improving mortality or quality of life. 2, 5
• Do not ignore interval growth during surveillance—a nodule that enlarges by ≥3 mm in any dimension represents significant progression and warrants cytological evaluation regardless of baseline size. 2

Evidence Supporting Conservative Management

Why Your Small TR3 Nodule Does Not Need Immediate FNA

• The ACR TI-RADS system was specifically designed to reduce unnecessary biopsies by incorporating both sonographic risk features and size thresholds. 1
• Studies show that approximately 5% of partially cystic or mixed nodules are malignant, but the risk is substantially lower when the solid portion is <50% and lacks eccentric placement or microcalcifications. 6
• Your nodule's isoechoic appearance, regular margins, and peripheral (rather than central) vascularity are reassuring features associated with benign lesions. 2
• The malignancy rate for TR3 nodules is approximately 5%, and most malignancies in this category are small papillary carcinomas with excellent prognosis when detected during surveillance. 5

Safety of Surveillance for Small Nodules

• Active surveillance of small papillary carcinomas is safe, with low progression rates manageable through regular imaging follow-up. 2
• Even when TR3 nodules prove malignant, they are typically low-risk papillary microcarcinomas with 5-year survival approaching 100%. 7
• Adjusting size thresholds to biopsy smaller nodules would capture only a few additional malignancies while substantially increasing the number of benign nodules undergoing unnecessary procedures. 5

Summary of Your Specific Plan

1. Measure serum TSH now to exclude thyroid dysfunction. 3
2. No FNA is needed for either nodule at this time. 1, 2
3. Schedule ultrasound surveillance of the left TR3 nodule at 1 year, 3 years, and 5 years. 1
4. Proceed to FNA during surveillance only if:
   • The nodule grows to ≥2.5 cm, OR
   • The nodule develops suspicious features (microcalcifications, irregular margins, marked hypoechogenicity), OR
   • You develop compressive symptoms or suspicious lymphadenopathy 2
5. The right thyroid cyst requires no further evaluation. 1